Skip navigation

This site is intended for US healthcare professionals only.

Request Representative/Samples
Patients

Make the switch from IR to MOTPOLY XR

chart
  • For patients who are already on a single AED and will convert to MOTPOLY XR monotherapy, withdrawal of the concomitant AED should not occur until the therapeutic dosage of MOTPOLY XR is achieved and has been administered for at least 4 days. A gradual withdrawal of the concomitant AED over at least 6 weeks is recommended1
  • For patients with severe renal impairment, the maximum recommended dose of MOTPOLY XR is 300 mg1
  • MOTPOLY XR is not recommended in patients with severe hepatic impairment1
  • MOTPOLY XR may be taken with or without food1
  • MOTPOLY XR capsules should be swallowed whole with liquid. Patients should not open, chew, or crush the capsules1

AED=anti-epileptic drug.

MOTPOLY XR provides dosing convenience for new patients

Dosing recommendations for new starts1*

Chart
chart
  • For patients with mild or moderate hepatic impairment, the maximum recommended dosage is 300 mg. Use in patients with severe hepatic impairment is not recommended1
  • For patients with severe renal impairment, the maximum recommended dose of MOTPOLY XR is 300 mg1
  • Dose reduction may be necessary in patients with hepatic or renal impairment who are taking strong inhibitors of CYP3A4 and CYP2C91

* When not specified, the dosage is the same for monotherapy for partial‑onset seizures and adjunctive therapy for partial‑onset seizures.

† Monotherapy for partial-onset seizures only.

References: 1. Motpoly XR [package insert]. Piscataway, NJ: Aucta Pharmaceuticals, Inc.; 2023. 2. Vimpat [package insert]. Smyrna, GA: UCB, Inc.; 2021.

INDICATION

MOTPOLY XR is indicated for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

  • Antiepileptic drugs increase the risk of suicidal behavior and ideation. Monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors.

INDICATION

MOTPOLY XR is indicated for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

  • Antiepileptic drugs increase the risk of suicidal behavior and ideation. Monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors.
  • MOTPOLY XR may cause dizziness and ataxia in patients. Advise patients not to operate machinery or motor vehicles until they know how MOTPOLY XR affects them.
  • Obtain ECG before beginning MOTPOLY XR, and after titration to steady-state maintenance dose in patients with underlying proarrhythmic conditions or those on concomitant medications that affect cardiac conduction. Closely monitor these patients.
  • MOTPOLY XR may cause syncope in patients.
  • Gradually withdraw MOTPOLY XR to minimize the potential of increased seizure frequency.
  • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/multi-organ hypersensitivity has been reported and can be life-threatening or fatal. If signs or symptoms are present, immediately evaluate the patient. Discontinue MOTPOLY XR if there is no alternative etiology.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions in adults (≥10% and greater than placebo) are diplopia, headache, dizziness, nausea, and somnolence.

PREGNANCY: Based on animal data, MOTPOLY XR may cause fetal harm.

DRUG INTERACTIONS: Consider dose reduction in patients with renal or hepatic impairment taking strong inhibitors of CYP3A4 and CYP2C9.

Please refer to the full Prescribing Information and Medication Guide for MOTPOLY XR for additional important information.

You are about to leave the Motpoly XR healthcare provider website and will be visiting the Motpoly XR patient website to view the copay information.

Leave site

To request a visit from a representative or to receive samples:

Phone Icon

sales.support@auctapharma.com